Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics Inc demonstrates a focused strategy by prioritizing the development of its HER3-targeting ADC, EO-1022, which indicates a commitment to advancing innovative therapies within a challenging financial landscape. The company’s decision to execute a workforce reduction signifies prudent financial management aimed at conserving funds, enhancing operational efficiency while navigating the current biotechnology sector difficulties. Additionally, although there are revisions in revenue forecasts and expenditure adjustments, the emphasis on key product candidates such as ELVN-001 and ELVN-002 reinforces the potential for future growth, suggesting a calculated pathway towards sustainable development.

Bears say

Enliven Therapeutics's negative outlook is largely influenced by the recent decision to discontinue the development of EO-3021, a Claudin 18.2-targeting antibody-drug conjugate, due to its lower-than-expected efficacy demonstrated in Phase 1 trials. Despite the drug's good tolerance, its insufficient efficacy raises concerns about the potential return on investment and the viability of further development. This situation has led to a downward revision of the company's future financial prospects and overall valuation.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.